drugset / Trial / NCT04017832

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

NCT04017832

Phase 3 Completed 1441 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe). Participants will either get oral semaglutide or sitagliptin - which treatment is decided by chance. Participants will get 2 tablets a day to take first thing in the morning on an empty stomach. Only 1 tablet has study medicine in it. The other tablet is a dummy medicine (placebo). After taking the semaglutide tablet, participants may not eat or drink anything for at least 30 minutes. After the 30 minutes, participants must take the sitagliptin tablet. Then participants can have their first meal of the day and take any other medicines they may need, including their metformin. The study will last for about 7 months (33 weeks). Participants will have 8 clinic visits and 1 phone call with the study doctor. At all 8 of the clinic visits, participants will have blood samples taken.

Timeline

Start
2019-07-29
Primary completion
2021-10-27
Completion
2021-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 3 mg Oral
Subject Semaglutide Peptide 7 mg Oral
Subject Semaglutide Peptide 14 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral